STM JOURNALS

International Journal of
Vaccines

ISSN: 3048-5681
Volume 2, Issue 1, 2025
January–June
DOI (Journal): 10.37591/IJV

https://journals.stmjournals.com/ijv

Review IJV

The Power of Genetic Engineering in Revolutionizing Vaccines

Ramdas Bhat[1,*], Preeti Shanbhag[2], Sinchana S. Bhat[3], Megha M.[3], Kavana D.K.[3], Rithin K.[3]

Abstract

Genetic engineering techniques, including recombinant subunit, viral vector, and nucleic acid vaccines have transformed the landscape of vaccine development. These novel approaches offer precise antigen design, enhanced safety profiles, and rapid adaptability to emerging pathogens. Key advantages include improved efficacy through targeted immune responses, increased safety due to the absence of live pathogens, and the ability to modify vaccines to address new variants or diseases quickly. Notable success stories, such as the hepatitis B vaccine and the recent mRNA-based COVID-19 vaccines, demonstrate the transformative potential of this technology. However, challenges persist in areas of production scalability, regulatory approval processes, and public perception. The effectiveness and broad acceptance of genetically modified vaccinations depend on resolving these problems. The field holds promising prospects for personalized vaccines tailored to individual genetic profiles, universal flu vaccines targeting conserved viral regions, and therapeutic vaccines for chronic diseases. As genetic engineering techniques continue to evolve, they have the potential to dramatically reshape our approach to disease prevention and treatment. This review explores the transition from conventional vaccine approaches to genetically engineered methods, examining their advantages, challenges, and future prospects. It aims to provide a comprehensive overview of how genetic engineering is revolutionizing vaccine development, offering hope for more effective, accessible, and adaptable solutions to global health challenges in the 21st century and beyond.

Keywords: Genetic engineering, global health, mRNA, personalized medicine, vaccines, viral vectors.

INTRODUCTION

Since the momentous and pioneering research conducted by Edward Jenner in the year 1796, which specifically focused on the eradication of smallpox, vaccines have undeniably emerged as an indispensable element within the framework of public health initiatives [1]. For an extensive duration spanning nearly two centuries, the methodologies employed in vaccine development were predominantly anchored in empirical strategies that utilized either attenuated or inactivated forms of pathogenic organisms. Nonetheless, the advent of genetic engineering during the latter part of the twentieth century catalyzed a significant paradigm shift that fundamentally transformed the landscape of vaccine research as we understand it today [2]. The inception of a novel era in the design and production of vaccines commenced in the year 1986, marked by the official approval of the very first genetically engineered vaccine targeting hepatitis B, a groundbreaking achievement that was made feasible through the revolutionary advancements in recombinant DNA technology that emerged in the 1970s [3].

The role of genetic engineering has grown increasingly pivotal in the realm of contemporary

***Author for Correspondence**
Ramdas Bhat
E-mail: ramdas21@gmail.com

[1]Associate Professor, Department of Pharmacology, Srinivas College of Pharmacy, Mangalore, Karnataka, India
[2]PG Scholar, Department of Pharmacology, Srinivas College of Pharmacy, Mangalore, Karnataka, India
[3]UG Scholar, Department of Pharmacology, Srinivas College of Pharmacy, Mangalore, Karnataka, India

Received Date: October 15, 2024
Accepted Date: October 25, 2024
Published Date: October 29, 2024

Citation: Ramdas Bhat, Preeti Shanbhag, Sinchana S. Bhat, Megha M., Kavana D.K., Rithin K. The Power of Genetic Engineering in Revolutionizing Vaccines. International Journal of Vaccines. 2025; 2(1): 18–27p.

vaccine research, primarily attributable to the myriad advantages it presents in optimizing vaccine development processes. This cutting-edge approach facilitates the meticulous design of vaccine antigens by concentrating on distinct components of pathogens that are most likely to provoke robust and effective immune responses within the human host. Furthermore, this innovative technique significantly enhances safety protocols by substantially reducing the necessity to cultivate large quantities of potentially harmful bacteria or viruses that could pose health risks [4]. In addition to these safety improvements, genetically engineered vaccines typically offer enhanced scalability, which is instrumental in enabling expedited production capabilities in larger volumes; this aspect is particularly crucial when it comes to effectively responding to the emergence of global pandemics and public health crises. Moreover, the inherent adaptability of these advanced genetic engineering techniques allows for swift and efficient responses to newly emerging or rapidly mutating pathogens, as exemplified by the remarkably rapid development and deployment of mRNA vaccines in response to the COVID-19 pandemic [5].

As we progress further into the complexities and challenges of the twenty-first century, the field of genetic engineering is significantly expanding the horizons of vaccine development and innovation. This includes a range of novel technologies, such as mRNA vaccines that fundamentally transform human cells into factories for producing antigens, as well as DNA vaccines that deliver genetic instructions directly into the body's cells, thereby reshaping our strategic approach to both disease prevention and therapeutic interventions [6]. This comprehensive review article will delve into the various genetic engineering techniques that are currently being employed in the domain of modern vaccine development, thoroughly examining their respective advantages, challenges, and the promising potential they embody for enhancing global health outcomes. By effectively harnessing the transformative power of genetic engineering, we are on the cusp of entering a new and unprecedented age of vaccine technology, characterized by the capability to address an increasingly broad spectrum of diseases while simultaneously improving the overall health outcomes on a global scale.

TRADITIONAL VACCINE DEVELOPMENT VS. GENETIC ENGINEERING APPROACHES

Traditional vaccine development methods have established several key approaches [7]. Vaccines that use weakened forms of pathogens (live attenuated vaccines) fight diseases like measles, mumps, and rubella. Vaccines containing killed pathogens (inactivated vaccines) are used in flu and polio prevention. Vaccines that use specific parts of pathogens like proteins or carbohydrates (subunit vaccines) create immune responses, as seen in hepatitis B prevention. Vaccines that work by neutralizing bacterial toxins (toxoid vaccines) are effective against tetanus and diphtheria.

These traditional methods, while successful, have significant limitations [8]. Development often takes more than ten years from research to public use. Safety issues exist, particularly with (live attenuated vaccines), which may cause mild symptoms or rarely return to their dangerous form. Some pathogens are hard to grow in laboratories, making vaccine production difficult or impossible [9]. Traditional vaccines also struggle against quickly changing pathogens or those with complex life cycles [10].

Genetic engineering has transformed vaccine development by addressing these limitations. This modern method uses recombinant DNA technology to create specific antigens and new delivery methods [11]. One type is recombinant (subunit vaccines), where scientists insert genes for target antigens into yeast, bacteria, or mammalian cells to produce large amounts of the antigen. The hepatitis B and HPV vaccines use this technology. Another approach uses viral vectors, where scientists modify harmless viruses to carry genes from dangerous pathogens. AstraZeneca and Johnson & Johnson used this method for their COVID-19 vaccines [12].

Nucleic acid vaccines represent a breakthrough. These include DNA vaccines using plasmids and RNA vaccines, like the Pfizer-BioNTech and Moderna COVID-19 vaccines, which tell cells to make viral proteins [13]. These genetically engineered vaccines are safer because they don't use live pathogens, can be made faster and in larger quantities, and can be easily changed to fight new variants [14].

Recent advances in genetic engineering have created even more innovative vaccines. Self-amplifying RNA (saRNA) vaccines contain extra genetic instructions that help cells make multiple copies of the antigen-encoding RNA, potentially creating stronger and longer-lasting immune responses with smaller doses [4]. Synthetic biology now allows for "plug-and-play" vaccine designs, like Moderna's platform for personalized cancer vaccines, which scientists can quickly adapt for new pathogens or cancer types [15].

Current research explores gene editing technologies like CRISPR-Cas9 to make better (live attenuated vaccines) by precisely changing virus genes [16]. New delivery systems, such as lipid nanoparticles that target specific cells, are improving vaccine effectiveness and reducing side effects. Scientists are also working on pan-coronavirus vaccines to protect against multiple coronavirus strains, including possible future threats. These new technologies represent the future of vaccine development, offering faster responses to new diseases, more personalized vaccines, and solutions to previously difficult disease challenges [17].

KEY GENETIC ENGINEERING TECHNIQUES IN VACCINE DEVELOPMENT

Recombinant DNA technology has fundamentally transformed the landscape of vaccine development by providing scientists with the unprecedented capability to insert specific genes that encode for particular antigens directly into host cells, thereby facilitating the production of substantial quantities of these antigens which can subsequently be utilized in the formulation of vaccines [18]. This innovative methodological framework serves as the underpinning for a multitude of contemporary vaccines, prominently including those designed to combat hepatitis B as well as human papillomavirus (HPV). The procedural technique encompasses a series of intricate steps which involve the isolation of the gene responsible for coding a specific antigen, the subsequent insertion of this gene into a plasmid vector, and the eventual introduction of this plasmid vector into a host cellular environment, which is frequently comprised of bacterial, yeast, or mammalian cells, all aimed at achieving large-scale production of the requisite antigens [19].

RNA vaccines represent a groundbreaking and transformative advancement in the field of vaccinology that has garnered considerable attention and interest. These novel vaccines employ messenger RNA (mRNA), which is specifically designed to encode the desired antigen, effectively instructing the body's cells upon entry to synthesize the antigen, thereby initiating a robust immunological response. The COVID-19 vaccines developed by the pharmaceutical companies Pfizer-BioNTech and Moderna serve as exemplary illustrations of the remarkable potential inherent in this innovative technology. One of the most compelling features of RNA vaccines is their capacity for rapid design and manufacturing processes, which significantly enhances their value and utility in responding to emerging pathogens or newly identified variants of existing pathogens [20].

In addition to RNA vaccines, viral vector vaccines and DNA vaccines represent two additional and notable genetic engineering methodologies that have made significant contributions to vaccine technology. Viral vector vaccines utilize genetically modified viruses, such as adenoviruses, to facilitate the delivery of genes that encode for the target antigen directly into the cells of the host [21]. The pharmaceutical companies AstraZeneca and Johnson & Johnson have successfully employed this state-of-the-art technology in the creation of their respective COVID-19 vaccines [12, 22]. Conversely, DNA vaccines operate under a different mechanism by introducing plasmid DNA that encodes the antigen directly into the cellular structures of the body. Although no DNA vaccines have thus far received regulatory approval for human use, they exhibit considerable promise in the realm of veterinary medicine and are currently the subject of ongoing human clinical trials that are exploring their potential applications (Figure 1) [21].



Figure 1. Vaccine production using recombinant DNA technology.
**The respective image represents the author's original work. Vaccine production by rDNA technology.*

ADVANTAGES OF GENETICALLY ENGINEERED VACCINES

Genetically engineered vaccines present a multitude of significant advantages when compared to the more conventional approaches employed in vaccine development and administration. To begin with, the foremost advantage that stands out is their markedly improved safety profile, which is critical in ensuring the well-being of vaccine recipients. In contrast to live attenuated vaccines that utilize pathogens that have been weakened but still retain their capacity for replication, genetically engineered vaccines typically comprise only specific, non-infectious components derived from the pathogen in question, thereby effectively eliminating the potential risk of any infection arising from the vaccine itself. This characteristic is especially advantageous for individuals who are immunocompromised, as these individuals may face heightened risks associated with receiving live vaccines, thus underscoring the importance of this safety enhancement in clinical practice [20].

The efficacy of genetically engineered vaccines can frequently be augmented through meticulous selection and design of antigens, which are the components that stimulate an immune response. By concentrating efforts on the most immunogenic portions of a pathogen, these innovative vaccines are capable of provoking immune responses that are not only stronger but also more specifically targeted towards the pathogen, thereby increasing their overall effectiveness. Moreover, the process of genetic engineering facilitates the incorporation of molecular adjuvants – substances that are known to enhance the immune response – directly within the vaccine formulation, which serves to further bolster the efficacy of the resultant vaccine product [23].

Perhaps one of the most remarkable and significant advantages associated with genetically engineered vaccines lies in the unprecedented speed at which they can be developed and produced, a factor that is paramount in the context of public health. In stark contrast to traditional vaccine development methodologies, which may span several years and involve complex processes, the application of genetic engineering techniques has the capacity to dramatically reduce this timeline to mere months or weeks. The swift development and deployment of COVID-19 mRNA vaccines serves as a compelling testament to the advantages conferred by such technologies. Furthermore, the adaptability of these vaccines is noteworthy, as they can be rapidly modified to effectively target new variants or emerging pathogens, thereby providing invaluable tools for pandemic preparedness and response strategies [24].

CASE STUDIES: SUCCESS STORIES IN GENETIC ENGINEERING AND VACCINES

The landscape of vaccine research has undergone a dramatic transformation through genetic engineering advancements, presenting revolutionary solutions to significant public health challenges [25]. The spectrum of achievements ranges from groundbreaking mRNA vaccines targeting COVID-19 to successful vaccines against HPV and Ebola, demonstrating how genetic engineering has expanded the boundaries of infectious disease prevention. These technological innovations have enabled more rapid and precise vaccine manufacturing processes, simultaneously improving both safety profiles and efficacy while broadening their potential applications. Looking ahead through 2024 and 2025, these developments continue their evolution, adapting to counter emerging viral threats and new infectious diseases [4].

Among the pioneering achievements in genetic engineering and vaccine development, the hepatitis B vaccine stands as a landmark accomplishment. Scientists achieved a breakthrough by utilizing recombinant DNA technology to produce hepatitis B surface antigen within yeast cells, eliminating the need for live virus particles. This innovative approach has led to a substantial decrease in global hepatitis B infection rates, significantly reducing the incidence of severe complications including liver cirrhosis and cancer [26]. Compared to previous methodologies using (inactivated vaccines) or (live attenuated vaccines), this technique demonstrated superior safety and efficacy profiles [27]. The hepatitis B vaccine maintains its crucial position in global immunization programs, with continuous improvements anticipated through 2024 and beyond [28].

The development of rotavirus vaccines represents another significant triumph in genetic engineering applications. Through the creation of vaccines like Rotarix and RotaTeq (live attenuated vaccines), scientists addressed a major cause of severe childhood diarrhea. Prior to vaccine availability, rotavirus infections resulted in millions of hospitalizations and thousands of fatalities annually, with developing nations bearing the heaviest burden [29]. The implementation of these vaccines has led to a marked reduction in rotavirus-related hospitalizations and mortality rates worldwide [30]. Genetic engineering techniques facilitated the development of vaccines offering sustained immunity with minimal adverse effects, particularly benefiting regions with limited healthcare infrastructure [31].

The Lyme disease vaccine exemplifies another innovative application of genetic engineering in vaccine development. Scientists engineered a vaccine using the surface antigen (OspA) of *Borrelia burgdorferi* bacteria (subunit vaccines), designed to prevent infection transmission from ticks to humans [32]. Despite its eventual market withdrawal due to insufficient demand, this vaccine demonstrated the potential for developing highly targeted immunization solutions [33]. Current discussions in 2024 continue to explore similar approaches for both Lyme disease and other emerging tick-borne infections [34].

An exciting frontier in vaccine technology has emerged with the concept of universal vaccines [25]. Unlike conventional vaccines targeting specific pathogens, these innovative solutions aim to provide comprehensive protection against multiple variants. The development of genetically engineered cellular vaccines mimicking natural immune responses shows promise in offering broader protection across various pathogen types [35]. This universal approach could revolutionize immunization strategies by providing unified solutions for multiple infectious threats. Significant advancements in this field, particularly targeting respiratory viruses and influenza strains, are expected throughout 2024 and 2025 [36].

Recent achievements in COVID-19 vaccine development further illustrate the power of genetic engineering. The successful creation of mRNA vaccines by Pfizer-BioNTech and Moderna represents a significant milestone in vaccine technology. These vaccines utilize innovative approaches to instruct cells to produce the SARS-CoV-2 spike protein, triggering robust immune responses. Their adaptability to target new variants, including emerging strains like Omicron KP.2, demonstrates the flexibility and rapid response capabilities of genetic engineering in vaccine development [37].

The development of viral vector vaccines, exemplified by the Oxford/AstraZeneca and Johnson & Johnson vaccines, showcases another successful application of genetic engineering. These vaccines employ modified adenoviruses to deliver genetic instructions for producing viral proteins, effectively training the immune system to recognize and combat the virus. This technology has proven particularly valuable during the COVID-19 pandemic and holds promise for addressing future infectious disease challenges [21].

Novavax's protein subunit vaccine approach represents yet another successful application of genetic engineering, offering an alternative for individuals who may not be suitable candidates for mRNA-based vaccines. This diversity in vaccine platforms, all enabled by genetic engineering, ensures broader accessibility and effectiveness across different population groups [38].

Looking toward the future, genetic engineering continues to drive innovations in vaccine development. Researchers are exploring new delivery systems, enhancing vaccine stability, and developing more efficient production methods. The ability to rapidly modify vaccines in response to new variants, as demonstrated during the COVID-19 pandemic, highlights the adaptability and responsiveness of genetically engineered vaccines [39]. Global vaccination initiatives, supported by programs like COVAX, continue to work toward ensuring equitable access to these advanced vaccine technologies [40, 41].

CHALLENGES AND ETHICAL CONSIDERATIONS

Despite the considerable potential that genetically engineered vaccines hold for revolutionizing preventive medicine, they encounter a myriad of intricate technical challenges that hinder both their development and production processes, as evidenced by the extensive research documented in previous studies [41]. In the case of RNA vaccines, one of the principal obstacles that researchers face is the inherent instability of mRNA molecules, which necessitates meticulous formulation strategies and stringent cold chain storage protocols to preserve their integrity and efficacy throughout the distribution process. Furthermore, for DNA vaccines, the ongoing difficulties associated with ensuring the efficient uptake of plasmid DNA by host cells, along with the subsequent expression of the encoded antigens, represent significant hurdles that demand innovative solutions and persistent research efforts. In addition to these scientific challenges, the scaling up of production for these cutting-edge vaccines frequently necessitates the establishment of novel manufacturing processes and facilities, which can prove to be both time-consuming and financially burdensome, thereby complicating the overall implementation of these technologies [42].

Regulatory barriers present yet another formidable obstacle that must be navigated in the quest for the successful deployment of genetically engineered vaccines. As these innovative technologies are still in their relative infancy, regulatory frameworks are continually being formulated and refined to keep pace with the rapid advancements in scientific knowledge and application. Consequently, regulatory bodies find themselves in the challenging position of needing to strike a delicate balance between the potential benefits associated with expedited vaccination strategies during public health emergencies and the imperative for thorough and comprehensive safety assessments, particularly in the context of global pandemics. This intricate balancing act often results in protracted and complex approval processes that can delay the timely dissemination of these vital public health tools [43].

The widespread acceptance and integration of genetically engineered vaccines into public health initiatives are significantly impeded by prevailing issues related to public perception and vaccine hesitancy, which collectively present substantial challenges to their adoption. The proliferation of misinformation and widespread misunderstandings concerning the principles of genetic engineering can exacerbate skepticism and foster resistance among segments of the population [44]. To effectively cultivate public trust in these novel interventions, it is of paramount importance that clear and transparent communication regarding the scientific underpinnings of these vaccines, their safety profiles, and the numerous benefits they confer is prioritized. Moreover, ethical considerations surrounding genetic modification, including unfounded concerns related to the alteration of human DNA – despite the current vaccine technologies not posing such risks – must be adequately addressed through proactive public engagement and comprehensive educational initiatives aimed at demystifying these advancements [45].

FUTURE PROSPECTS

The prospective landscape of vaccine development is imbued with a plethora of exhilarating possibilities, wherein personalized vaccines stand prominently at the leading edge of this scientific frontier. These innovative vaccines possess the remarkable capability to be intricately tailored to cater specifically to the nuances of cancer immunotherapy, taking into consideration the distinctive characteristics intrinsic to an individual tumor or the unique genetic makeup of a patient. Such pioneering methodologies hold the potential to significantly enhance the effectiveness of vaccines while concurrently minimizing any adverse effects that may arise because of the treatment. A notable exemplar of this avant-garde approach can be found in moderna's personalized cancer vaccine platform, which adeptly integrates the genetic sequencing of a patient's tumor with cutting-edge mRNA vaccine technology, thereby exemplifying the early stages of this transformative initiative.

In addition to this, another captivating domain within the realm of vaccine research is the development of universal influenza vaccinations. Each year, the existing influenza vaccines necessitate modifications to accurately reflect the current strains that are actively circulating within the population. To address this challenge, advanced genetic engineering techniques are actively being employed to formulate vaccines that specifically target conserved regions of the influenza virus, which holds the promise of delivering broad-spectrum protection against a multitude of viral strains while simultaneously alleviating the necessity for annual vaccination campaigns. Furthermore, analogous methodologies are currently under investigation for other viruses that exhibit rapid mutation rates, thereby expanding the potential applicability of this innovative approach.

Moreover, the application of vaccine technology to the management and treatment of chronic diseases represents a field of research that is experiencing an unprecedented level of intensity and dedication. In this context, researchers are diligently exploring the potential of therapeutic vaccines aimed at addressing a variety of chronic conditions, including but not limited to diabetes, hypertension, and Alzheimer's disease.

The envisioned therapeutic vaccines would serve to educate and empower the immune system to specifically target and neutralize the factors responsible for disease progression, thereby potentially offering long-lasting management solutions or even definitive cures for these pervasive health challenges. Although these initiatives remain in the nascent stages of development, the implications of such innovative approaches have the potential to profoundly revolutionize the paradigms surrounding the treatment and management of chronic diseases.

CONCLUSIONS

Genetic engineering has transformed vaccine development, from mRNA COVID-19 vaccines to potential personalized cancer treatments. Prospects include tailored vaccines based on individual genetics, universal flu protection, and therapeutic vaccines for chronic diseases. While these advancements promise more effective and accessible healthcare, realizing their potential requires ongoing research, regulatory navigation, and public trust-building. As genetic engineering integrates further into vaccinology, it could reshape global health strategies, offering innovative solutions to current and future health challenges.

REFERENCES

1. WWW.CDC.GOV. History of smallpox [Online]. CDC. 2019. Available from: https://www.cdc.gov/smallpox/history/history.html#:~:text=The%20basis%20for%20vaccination%20began.
2. Montero DA, Vidal RM, Velasco J, Carreño LJ, Torres JP, Benachi MA, et al. Two centuries of vaccination: historical and conceptual approach and future perspectives. Front Public Health. 2023;11. doi:10.3389/fpubh.2023.1326154.
3. Pattyn J, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccines. J Infect Dis. 2021;224(S4):343–351. doi:10.1093/infdis/jiaa668.
4. Al Fayez N, Nassar MS, Alshehri AA, Alnefaie MK, Almughem FA, Alshehri BY, et al. Recent advancement in mRNA vaccine development and applications. Pharmaceutics. 2023;15(7):1972. doi:10.3390/pharmaceutics15071972.
5. Rando HM, Lordan R, Lee AJ, Naik A, Wellhausen N, Sell E. Application of traditional vaccine development strategies to SARS-CoV-2. ASM J. 2023;8(2):e00927-22. doi:10.1128/msystems.00927-22.
6. Schlake T, Thess A, Fotin-Mleczek M, Kallen K-J. Developing mRNA-vaccine technologies. RNA Biol. 2012;9(11):1319–1330. doi:10.4161/rna.22269.
7. Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell. 2021;184(6):1589–1603. doi:10.1016/j.cell.2021.02.030.
8. Types of Vaccine. India Science, Technology & Innovation - ISTI Portal [Online]. www.indiascienceandtechnology.gov.in. Available from: https://www.indiascienceandtechnology.gov.in/covid-19-vaccine/types-vaccine.
9. Minor PD. Live attenuated vaccines: historical successes and current challenges. Virol. 2015;479–480:379–392. doi:10.1016/j.virol.2015.03.032.
10. Kennedy RB, Ovsyannikova IG, Palese P, Poland GA. Current challenges in vaccinology. Front Immunol. 2020;11:1181. doi:10.3389/fimmu.2020.01181.
11. Kozak M, Hu J. DNA vaccines: their formulations, engineering and delivery. Vaccines. 2024;12(1):71. doi:10.3390/vaccines12010071.
12. Daniali M, Mousavi T, Abdollahi M. Biological Products in Medicine. In: Encyclopedia of Toxicology. 2nd edition. Amsterdam: Elsevier; 2024. 117–132.
13. Jain S, Venkataraman A, Wechsler ME, Peppas NA. Messenger RNA-based vaccines: past, present, and future directions in the context of the COVID-19 pandemic. Adv Drug Deliv Rev. 2021;179:114000. doi:10.1016/j.addr.2021.114000.
14. Matić Z, Šantak M. Current view on novel vaccine technologies to combat human infectious diseases. Appl Microbiol Biotechnol. 2022;106:25–56. doi:10.1007/s00253-021-11713-0.
15. Ghattas M, Dwivedi G, Lavertu M, Alameh MG. Vaccine technologies and platforms for infectious diseases: current progress, challenges, and opportunities. Vaccines. 2021;9(12):1490. doi:10.3390/vaccines9121490.
16. Zahedipour F, Zahedipour F, Zamani P, Jaafari MR, Sahebkare A. Harnessing CRISPR technology for viral therapeutics and vaccines: from preclinical studies to clinical applications. Virus Res. 2024;341:199314. doi:10.1016/j.virusres.2024.199314.
17. Bezbaruah R, Chavda VP, Nongrang L, Alom S, Deka K, Kalita T, et al. Nanoparticle-based delivery systems for vaccines. Vaccines. 2022;10(11):1946. doi:10.3390/vaccines10111946.
18. Khan S, Ullah MW, Siddique R, Nabi G, Manan S, Yousaf M, et al. Role of recombinant DNA technology to improve life. J Genet Eng Biotechnol. 2016;14(1):17. doi:10.1155/2016/2405954.
19. Murray K, Stahl S, Ashton-Rickardt PG. Genetic engineering applied to the development of vaccines. Philos Trans R Soc Lond B Biol Sci. 1989 ;324(1224):31. doi:10.1098/rstb.1989.0060.
20. Hogan MJ, Pardi N. mRNA vaccines in the COVID-19 pandemic and beyond. Annu Rev Med. 2022;73:17–39. doi:10.1146/annurev-med-042420-112725.

21. Deng S, Liang H, Chen P, Li Y, Li Z, Fan S, et al. Viral vector vaccine development and application during the COVID-19 pandemic. Vaccines. 2022;10(7):1450. doi:10.3390/microorganisms10071450.
22. Joudeh AI, Lutf AQ, Mahdi S, Tran G. Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review. Vaccine. 2023;41(26):3801–3812. doi:10.1016/j.vaccine.2023.05.048.
23. Lee J, Kumar SA, Jhan YY, Bishop CJ. Engineering DNA vaccines against infectious diseases. Acta Biomater. 2018;15(80):31–47. doi:10.1016/j.actbio.2018.08.033.
24. Das S, Kar SS, Samanta S, Banerjee J, Giri B, Dash SK. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. Immunol Res. 2022;70(3):289–315. doi:10.1007/s12026-022-09265-0.
25. McCullers JA, Dunn JD. Advances in vaccine technology and their impact on managed care. Pharm Ther. 2008;33(1):35.
26. Zhao H, Zhou X, Zhou YH. Hepatitis B vaccine development and implementation. Hum Vaccin Immunother. 2020;16(7):1533–1544. doi:10.1080/21645515.2020.1732166.
27. Flores JE, Thompson AJ, Ryan M, Howell J. The global impact of hepatitis B vaccination on hepatocellular carcinoma. Vaccines. 2022;10(5):793. doi:10.3390/vaccines10050793.
28. Al-Busafi SA, Alwassief A. Global perspectives on the hepatitis B vaccination: challenges, achievements, and the road to elimination by 2030. Vaccines. 2024;12(3):288. doi:10.3390/vaccines12030288.
29. Dhalaria P, Kapur S, Singh AK, Verma A, Priyadarshini P, Taneja G. Potential impact of rotavirus vaccination on reduction of childhood diarrheal disease in India: An analysis of National Family Health Survey-5. Vaccine: X. 2023;14:100319. doi:10.1016/j.jvacx.2023.100319.
30. Cárcamo-Calvo R, Muñoz C, Buesa J, Rodríguez-Díaz J, Gozalbo-Rovira R. The rotavirus vaccine landscape, an update. Pathogens. 2021;10(5):520. doi:10.3390/pathogens10050520.
31. Burnett E, Parashar U, Tate J. Rotavirus vaccines: effectiveness, safety, and future directions. Pediatr Drugs. 2018;20:223–233. doi:10.1007/s40272-018-0283-3.
32. Chen WH, Strych U, Bottazzi ME, Lin YP. Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights. Expert Rev Vaccines. 2022;21(10):1405–1417. doi:10.1080/14760584.2022.2102484.
33. Pine M, Arora G, Hart TM, Bettini E, Gaudette BT, Muramatsu H, et al. Development of an mRNA-lipid nanoparticle vaccine against Lyme disease. Mol Ther. 2023;31(9):2702–2714. doi:10.1016/j.ymthe.2023.07.022.
34. Gomes-Solecki M, Arnaboldi PM, Backenson PB, Benach JL, Cooper CL, Dattwyler RJ, et al. Protective immunity and new vaccines for Lyme disease. Clin Infect Dis. 2020;70(8):1768–1773. doi:10.1093/cid/ciz872.
35. Cooper A, Sidaway A, Chandrashekar A, Latta E, Chakraborty K, Yu J, et al. A genetically engineered, stem-cell-derived cellular vaccine. Cell Rep Med. 2022;3(12):100843. doi:10.1016/j.xcrm.2022.100843.
36. Grohskopf LA. Prevention and control of seasonal influenza with vaccines: Recommendations of the advisory committee on immunization practices—United States, 2024–25 influenza season. MMWR. Recommendations and Reports. 2024;73.
37. Chavda VP, Jogi G, Dave S, Patel BM, Vineela Nalla L, Koradia K. mRNA-Based Vaccine for COVID-19: They are new but not unknown. Vaccines. 2023;11(3):507. doi:10.3390/vaccines 11030507.
38. Park HJ, Bang YJ, Kwon SP, Kwak W, Park SI, Roh G, et al. Analyzing immune responses to varied mRNA and protein vaccine sequences. Vaccines. 2023;8(1):84. doi:10.1038/s41541-023-00684-0.
39. Chavda VP, Bezbaruah R, Valu D, Patel B, Kumar A, Prasad S, et al. Adenoviral vector-based vaccine platform for COVID-19: current status. Vaccines. 2023;11(2):432. doi:10.3390/vaccines 11020432.
40. Ma KC, Surie D, Lauring AS, Martin ET, Leis AM, Papalambros L. et al. Effectiveness of updated 2023–2024 (Monovalent XBB. 1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA. 2.86/JN. 1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, medRxiv. 2024:2024-06. Clin Infect Dis. 2024. doi:10.1093/cid/ciae405.

41. Brisse M, Vrba SM, Kirk N, Liang Y, Ly H. Emerging concepts and technologies in vaccine development. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.583077.
42. Blenke EO, Örnskov E, Schöneich C, Nilsson GA, Volkin DB, Mastrobattista E, et al. The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case. J Pharm Sci. 2023;112(2):386–403. doi:10.1016/j.xphs.2022.11.001.
43. Mennella C, Maniscalco U, De Pietro G, Esposito M. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. Heliyon. 2024;10(4):e26297. doi:10.1016/j.heliyon.2024.e26297.
44. Galagali PM, Kinikar AA, Kumar VS. Vaccine hesitancy: obstacles and challenges. Curr Pediatr Rep. 2022;10(4):241–248. doi:10.1007/s40124-022-00278-9.
45. Bang Petersen M, Bor A, Jørgensen F, Lindholt MF. Transparent communication about negative features of COVID-19 vaccines decreases acceptance but increases trust. Proc Natl Acad Sci U S A. 2021;118(29):e2024597118. doi:10.1073/pnas.2024597118.

